Roche to snag cloud-based tool in Viewics buyout

roche
Roche's acquisition of Viewics is slated to close Nov. 21.

Roche announced on Friday that it would acquire software company Viewics, picking up its data-driven, laboratory business analytics platform.

Under the agreement, which is slated to close this month, Roche will acquire all shares of Viewics, the company said in a statement. Financial details were not disclosed.

Viewics’ offerings enable the integration of big data from a range of IT systems—such as electronic medical records and laboratory information systems—in order to help customers make decisions to improve processes and performance in the lab.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Roche gets FDA nod for Zika-screening blood test

“The Viewics solution offers our customers insights at their fingertips, uncovering potential value and profitability drivers in lab operations, and indicators to improve overall quality of care,” said Roland Diggelmann, CEO of Roche Diagnostics, in the statement.

The HIPAA-compliant tool extracts and cleans data before it is transmitted to Viewics’ cloud-based analytics engine. There, machine-learning algorithms crunch the data to provide a comprehensive view of each patient from disparate sources of data.

RELATED: Roche partners with Senseonics, TypeZero on ‘artificial pancreas’

“The Viewics platform generates insights that can inform real-time decisions about costs, laboratory performance, and many other areas affecting today’s modern healthcare organizations,” said Viewics CEO Keith Laughman in the statement. “We are looking forward to working with our Roche colleagues in helping to support the lab’s critical role in healthcare delivery.”

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.